

<https://doi.org/10.48047/AFJBS.6.7.2024.3403-3412>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

## OVERVIEW OF DEMOGRAPHICS ASSOCIATED WITH RHEUMATOID ARTHRITIS: A NARRATIVE REVIEW

1. Talha Rehman

Second year MBBS

Hamdard College of Medicine and Dentistry

[rehmantalha454@gmail.com](mailto:rehmantalha454@gmail.com)

2. Tayyaba Hidayat

Third year MBBS

Jinnah sindh medical university

[tayyabahidayat13@gmail.com](mailto:tayyabahidayat13@gmail.com)

3. Neha

Third year MBBS

Jinnah sindh medical university

[nehamohan759@gmail.com](mailto:nehamohan759@gmail.com)

4. Bibi Samia Khan

Second year MBBS

Hamdard College of Medicine and Dentistry

[bibisamiakhan@gmail.com](mailto:bibisamiakhan@gmail.com)

5. Lareb sindhu Ghanghro

Second year MBBS

Hamdard College of Medicine and Dentistry

[larebsindhu89@gmail.com](mailto:larebsindhu89@gmail.com)

6. Muhammad Hussnain

Third year MBBS

Hamdard College of Medicine and Dentistry

[husnain.khan3649@gmail.com](mailto:husnain.khan3649@gmail.com)

Volume 6 issue 7 2024  
Received:01June2024  
Accepted:30June2024  
doi:10.48047/AFJBS.6.7.2024.3403-3412

#### ABSTRACT

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder primarily affecting the joints, leading to inflammation, pain, and progressive joint destruction. It is characterized by synovial hyperplasia, inflammatory cell infiltration, and the production of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). The etiology of RA involves a complex interplay of genetic, environmental, and immunological factors. Genetic predisposition, particularly the presence of HLA-DRB1 alleles, significantly increases the risk of developing RA. Environmental triggers, such as smoking and infections, may initiate or exacerbate the disease in genetically susceptible individuals.

The pathogenesis of RA includes the activation of immune cells and the release of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-1 (IL-1), and interleukin-6 (IL-6), which drive the inflammatory process and joint damage. Advances in understanding these molecular mechanisms have led to the development of targeted biological therapies, such as TNF inhibitors, IL-6 receptor antagonists, and Janus kinase (JAK) inhibitors, which have revolutionized RA management and significantly improved patient outcomes.

Despite these advancements, RA remains a major cause of disability and reduced quality of life. Early diagnosis and intervention are crucial for preventing irreversible joint damage and achieving disease remission. Diagnostic tools have evolved, with imaging techniques like ultrasound and magnetic resonance imaging (MRI) playing pivotal roles in early detection and monitoring of disease activity. Moreover, patient-centered care approaches emphasizing shared decision-making and personalized treatment plans are essential for optimal management.

Research continues to explore new therapeutic targets and strategies, including the role of the gut microbiome, novel biomarkers, and the impact of lifestyle modifications such as diet and physical activity. As our understanding of RA deepens, future directions aim to refine treatment algorithms, enhance early detection, and ultimately achieve a cure for this debilitating disease.

#### INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the joints and occasionally other tissues such as the skin, blood vessels, heart, lungs, and muscles (1). It leads to both joint-specific and systemic symptoms, and significantly raises the risk of cardiovascular disease (CVD), making it an independent risk factor (2). RA primarily affects the synovial membrane, cartilage, and bone, resulting in progressive disability, systemic complications, and higher mortality rates (3).

The pathophysiology of RA involves a complex interaction of genetic and environmental factors that trigger chronic synovial inflammation and joint damage (4). Beyond joint inflammation, RA patients are at heightened risk for CVD, experiencing increased cardiovascular events and

mortality despite lower circulating lipid levels, due to abnormal lipid functions (5). The patients with active RA, differently from the general population, have increased CV events and mortality, paradoxically associated with the reduced circulating lipid levels. In fact, the lipid functions are abnormal in RA (6). Interstitial lung disease (ILD) is a common extra-articular manifestation, contributing to RA morbidity and mortality (7).

RA is the most common inflammatory polyarthritis seen in outpatient settings, often associated with sleep disturbances and an increased risk of falls. Patients with RA frequently exhibit prolonged sleep latency, lower sleep efficiency, an increased number of awakenings and arousals, feelings of non-restorative sleep and daytime sleepiness (8, 9). Adults with rheumatoid arthritis (RA) have an increased risk of falls as well (10)

## **EPIDEMIOLOGY**

Rheumatoid arthritis is a prevalent systemic autoimmune disease that leads to chronic inflammation and irreversible damage to joints and bones (11). RA can affect individuals of any age and ethnicity, with prevalence increasing with age, reaching up to 2% in older populations (12). Globally, RA affects about 1% of adults, with women being 3-5 times more likely to develop the disease than men (13). The global prevalence ranges from 0.1% to 1%, being more common in developed countries (14-16). In 2017, the prevalence was 246.6 per 100,000 people, a 7.4% increase since 1990 (17).

Prevalence varies by region, being 0.5% in Europe, 1% in North America, and 0.1% in North Africa, but up to 2.8% in Mexico (18, 19). The prevalence in India is about 0.75%, comparable to developed countries (20). RA affects approximately 1% of the population over a lifetime and is four times more prevalent in women due to hormonal and genetic factors (21, 22). Disease incidence in women peaks around menopause. The concordance rate among monozygotic twins is 12-15% (23-25).

## **CAUSES & RISK FACTORS**

Genetic predisposition plays a significant role in RA, particularly genes within the HLA class II molecule-encoding locus. Specific HLA-DRB1 alleles are associated with increased risk for seropositive RA. Diet, body composition, and lifestyle factors also influence RA risk (26).

Obesity, increased BMI, and waist circumference are risk factors, while smoking is strongly linked to RA, likely due to its role in generating anticitrullinated peptide antibodies (ACPA) (27). RA patients are at higher risk for cardiovascular diseases, including atherosclerotic CVD, stroke, heart failure, and atrial fibrillation, with CV disease being a major cause of death in RA patients. (28-33).

## **LITERATURE REVIEW**

A study conducted in Japan in April 2016 aimed to describe clinical features of patients with rheumatoid arthritis. The study design was large observational cohort study with the sample size of 5479 patients. Male to female ratio was 771:4708 and mean age was 61.8 . The most common clinical manifestation was observed to be involvement of foot and ankle joint. The individual with foot involvement had more severe disease symptoms with increased limitations in daily life, decreased ability to perform tasks, and overall, a decreased sense of well-being and mental health as compared to the non-foot group (34).

A prospective study from Germany on 45 patients (18 males, 27 females, mean age 54) compared RA and psoriatic arthritis (PsA). RA was associated with flexor tenosynovitis, while PsA had extracapsular inflammation at the MCP level. The most common clinical manifestation was observed to be flexor tenosynovitis was strongly associated with RA while at the MCP level, extracapsular inflammation was associated with PsA (35).

In another study conducted in Netherlands between July 2013 and March 2020 aimed to describe clinical features related to rheumatoid arthritis. The study design was a prospective study with the sample size of 577 patients. Male to female ratio was 144:433 and mean age was 44. The most common clinical manifestation was observed to be intermetatarsal bursitis especially when synovitis or tenosynovitis are present, MTP tenderness, Juxta-articular synovitis, intra-articular synovitis and joint tenderness (36).

In yet another research conducted in Netherlands from June 2013 to March 2016 aimed to describe clinical features of patients with rheumatoid arthritis. The study design was a logistic regression with the sample size of 157 patients. Male to female ratio was 48:109 and mean age was 59. The most common clinical manifestation was observed to be intermetatarsal bursitis with

strong association with tenosynovitis. Metatarsalgia and arthritis, synovitis, osteitis, joint tenderness and swelling were also observed (37).

A study conducted in Malaysia from January 2018 to June 2021 aimed to describe characteristics of rheumatoid arthritis. The study design was retrospective study with the sample size of 732 patients. Male to female ratio was 109:623 and mean age was 58.1. The most common clinical feature was observed to be interstitial lung disease as an extra-articular manifestation. Non-specific interstitial pneumonia(NSIP) was the predominant pattern (38).

In one of the study conducted in Turkey aimed to describe characteristics of rheumatoid arthritis. The study design was retrospective study with the sample size of 87 patients. Male to female ratio was 23:64 and mean age was 59. The most common clinical feature was observed to be non-specific interstitial pneumonia, five patients had usual interstitial pneumonia, and one had nodules. Subpleural fibrosis increased the probability of RA-ILD by 6.9 times. In the group with ILD, the residual volume and total capacity were decreased compared to the other group (39).

A research conducted in Turkey aimed to describe characteristics of rheumatoid arthritis. The study design was retrospective study with the sample size of 87 patients. Male to female ratio was 9:78 and mean age was 59. The study examined temporomandibular joint involvement, noting no significant difference between elderly and young-onset RA (40).

Another study conducted in China from January 2013 and June 2021 aimed to describe complications of rheumatoid arthritis. The study design was retrospective study with the sample size of 6 patients. Male to female ratio was 1:5 and mean age was 33-64. The symptoms of meningitis or meningoencephalitis occurred after the onset of arthritis in five patients and before the onset of arthritis in one patient. The most common clinical features were observed to be Headache, hyper acute focal neurological deficits and seizures (41).

Research continues to explore new therapeutic targets and strategies, including the role of the gut microbiome, novel biomarkers, and the impact of lifestyle modifications such as diet and physical activity. As our understanding of RA deepens, future directions aim to refine treatment algorithms, enhance early detection, and ultimately achieve a cure for this debilitating disease.

**REFERENCES**

1. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737-45.
2. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. *Autoimmun Rev.* 2005 Mar;4(3):130-6. doi: 10.1016/j.autrev.2004.09.002. PMID: 15823498.
3. Ali AH, Carey EJ, Lindor KD. The management of autoimmunity in patients with cholestatic liver diseases. *Expert Rev Gastroenterol Hepatol* 2016;10:73–91.
4. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet.* (2016) 388:2023–38. doi: 10.1016/S0140-6736(16)30173-8
5. Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. *Nat Rev Rheumatol.* (2020) 6:361–79. doi: 10.1038/s41584-020-0428-y
6. Liao KP, Liu J, Lu B, Solomon DH, Kim SC. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. *Arthritis Rheumatol.* 2015 May;67(8):2004-10. doi: 10.1002/art.39165. PMID: 25917955; PMCID: PMC4418211.
7. O'Dwyer DN, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC. Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). *Eur J Intern Med.* 2013 Oct;24(7):597-603. doi: 10.1016/j.ejim.2013.07.004. Epub 2013 Aug 1. PMID: 23916467.
8. Sariyildiz MA, Batmaz I, Bozkurt M, Bez Y, Cetincakmak MG, Yazmalar L, et al. Sleep quality in rheumatoid arthritis: Relationship between the disease severity, depression, functional status and the quality of life. *J Clin Med Res* 2014;6:44-52.
9. Grewal GS, Amlani A, Hazlewood G. Sleep in rheumatoid arthritis: A systematic review and meta-analysis of objective sleep parameters. *Sleep* 2018;41:A340.
10. Armstrong C, Swarbrick CM, Pye SR, O'Neill TW. Occurrence and risk factors for falls in rheumatoid arthritis. *Ann Rheum Dis.* 2005 Nov;64(11):1602-4. doi: 10.1136/ard.2004.031195. Epub 2005 Apr 7. PMID: 15817660; PMCID: PMC1755283.
11. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. *Ann*

- Rheum Dis. 2006;65(7):845– 51. [PubMed ID: 16606649]. [PubMed Central ID: PMC1798205]. <https://doi.org/10.1136/ard.2006.051391>
12. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. *Arthritis Rheum.* 2003 Apr;48(4):917-26. doi: 10.1002/art.10897. PMID: 12687533.
  13. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. *Cells.* 2021;10(11):2857. doi:10.3390/cells10112857.
  14. Scublinsky, D.; Gonzalez, C.D. Quantifying Disease in Challenging Conditions: Incidence and Prevalence of Rheumatoid Arthritis. *J. Rheumatol.* 2016, 43, 1263–1264. [CrossRef]
  15. Guo, G.; Fu, T.; Yin, R.; Zhang, L.; Zhang, Q.; Xia, Y, et al. Sleep quality in Chinese patients with rheumatoid arthritis: Contributing factors and effects on health-related quality of life. *Health Qual. Life Outcomes* 2016, 14, 151. [CrossRef] [PubMed]
  16. Almutairi, K.; Nossent, J.; Preen, D.; Keen, H.; Inderjeeth, C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. *Rheumatol. Int.* 2021, 41, 863–877. [CrossRef] [PubMed]
  17. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. *Ann Rheum Dis.* 2019 Nov;78(11):1463-1471. doi: 10.1136/annrheumdis-2019-215920. Epub 2019 Sep 11. PMID: 31511227.
  18. Minichiello E, Semerano L, Boissier M. [Incidence, prevalence and severity of rheumatoid arthritis in the 21st century]. *Re vue du Rhumatisme Monographies.* 2017;84(4):303–10. French. <https://doi.org/10.1016/j.monrhu.2017.07.002>.
  19. Papadimitropoulos, E.; Brnabic, A.; Vorstenbosch, E.; Leonardi, F.; Moyano, S.; Gomez, D. The burden of illness of rheumatoid arthritis in Latin America—A systematic literature review. *Int. J. Rheum. Dis.* 2022, 25, 405–421. [CrossRef]
  20. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. *Rheumatol Int.* 1993;13:131–134.
  21. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. *Autoimmun Rev* 2005;4:130-6.

22. Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, Mantilla RD, Castellanos-de la Hoz J, Bernal-Macías S, et al. Gender differences in Latin-American patients with rheumatoid arthritis. *Gend Med*. 2012 Dec;9(6):490-510.e5. doi: 10.1016/j.genm.2012.10.005. PMID: 23217568.
23. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. *J Rheumatol Suppl*. 1996 Mar; 44:10-2. PMID: 8833045.
24. Aho K, Koskenvuo M, Tuominen J, et al. Occurrence of rheumatoid arthritis in a nationwide series of twins. *J Rheumatol* 1986;13:899- 902.
25. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. *Br J Rheumatol* 1993;32:903-7.
26. Balandraud N, Picard C, Reviron D, Landais C, Toussiro E, Lambert N, et al. HLA-DRB1 genotypes and the risk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis. *PLoS One*. 2013 May 30;8(5):e64108. doi: 10.1371/journal.pone.0064108. PMID: 23737967; PMCID: PMC3667843.
27. He J, Wang Y, Feng M, Zhang X, Jin YB, Li X, et al. Dietary intake and risk of rheumatoid arthritis-a cross section multicenter study. *Clin Rheumatol*. 2016 Dec;35(12):2901-2908. doi: 10.1007/s10067-016-3383-x. Epub 2016 Aug 23. PMID: 27553386; PMCID: PMC5118386.
28. Ljung L, Rantapää-Dahlqvist S. Abdominal obesity, gender and the risk of rheumatoid arthritis - a nested case-control study. *Arthritis Res Ther*. 2016 Nov 29;18(1):277. doi: 10.1186/s13075-016-1171-2. PMID: 27894341; PMCID: PMC5127000.
29. de Hair MJ, Landewé RB, van de Sande MG, van Schaardenburg D, van Baarsen LG, Gerlag DM, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. *Ann Rheum Dis*. 2013 Oct;72(10):1654-8. doi: 10.1136/annrheumdis-2012-202254. Epub 2012 Oct 27. PMID: 23104761; PMCID: PMC3786633.
30. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum* 2006;54:38–46.



31. Semb AG, Ik Dahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. *Nat Rev Rheumatol.* (2020) 6:361–79. doi: 10.1038/s41584-020-0428-y
32. Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. *BMC Rheumatol.* (2018) 2:10. doi: 10.1186/s41927-018-0014-y
33. Hand R. Rheumatoid arthritis – at the cross roads of inflammation and atherosclerosis!. *J Assoc Physicians India.* 2013;61:529.
34. Koichiro Yano, Katsunori Ikari, Eisuke Inoue, YuSakuma, Takeshi Mochizuki, NaokoKoenuma, et al. Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort. *PLoS One.* 2018 Sep 6;13(9).
35. Daniel B. Abrar, Christoph Schleich, Ralph Brinks, Christine Goertz, Matthias Schneider, et al. Differentiating rheumatoid and psoriatic arthritis: a systematic analysis of high-resolution magnetic resonance imaging features. *Skeletal Radiology* (2021) 50:531–541.
36. Bastiaan T. van Dijk, Fenne Wouters, Elise van Mulligen, Monique Reijnierse, Annette H.M. e tal. During development of rheumatoid arthritis, intermetatarsal bursitis may occur before clinical joint swelling: a large imaging study in patients with clinically suspect arthralgia. *Rheumatology* 2022;61:2805–2814.
37. Bastiaan T. van Dijk, YousraJ.Dakkak, XantheM.E.Matthijssen, Ellis Niemantsverdriet, Monique Reijnierse, et al. Intermetatarsal Bursitis, a Novel Feature of Juxtaarticular Inflammation in Early Rheumatoid Arthritis Related to Clinical Signs: Results of a Longitudinal Magnetic Resonance Imaging Study. *Arthritis Care Res (Hoboken).* 2022 Oct;74(10):1713-1722.
38. Ong Swee Gaik, Ding Hui Jen, Zuhani Abdul Hamid, Aida Abdul Aziz, Norazizah Ibrahim Wong. Predictors and radiological characteristics of rheumatoid arthritis-associated interstitial lung disease in a multiethnic Malaysian cohort. *Med J Malaysia.* 2022 May;77(3):292-299.
39. Genc AC, Ozturk Z, Kara AB, Turkoglu Genc F, Aydemir Y, Gunduz Y, et al. Assessment of the clinical features of rheumatoid arthritis-related interstitial lung

diseases: a retrospective evaluation. *Eur Rev Med Pharmacol Sci.* 2023 Sep;27(18):8486-8493.

40. Ilhanli M, Ilhanli I. Temporomandibular joint involvement in elderly onset and young onset rheumatoid arthritis patients. *Rev Assoc Med Bras (1992).* 2023 Aug 21;69(8):e20230411.
41. Fan S, Zhao J, Hou B, Liu M, Niu J, Zhou Y, et al. Rheumatoid meningitis: a rare neurological complication of rheumatoid arthritis. *Front Immunol.* 2023 Jun 7;14:1065650